Shots:

• The US FDA has approved FT designation for Bemcentinib to treat elderly patients with acute myeloid leukemia (AML) whose disease has relapsed
• The FDA’s Fast Track designation facilitates the development and expedite the review of therapy to treat serious conditions and fill an unmet medical need
• Bemcentinib (BGB324) is a first-in-class selective AXL inhibitor- currently being evaluated in P-II study for AML. BerGenBio plan to seek regulatory advice from the US FDA & EMA to determine the optimal regulatory path for Bemcentinib in relapsed AML

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Visinnovasjon